2024
Cardiometabolic characteristics of people with metabolically healthy and unhealthy obesity
Petersen M, Smith G, Palacios H, Farabi S, Yoshino M, Yoshino J, Cho K, Davila-Roman V, Shankaran M, Barve R, Yu J, Stern J, Patterson B, Hellerstein M, Shulman G, Patti G, Klein S. Cardiometabolic characteristics of people with metabolically healthy and unhealthy obesity. Cell Metabolism 2024, 36: 745-761.e5. PMID: 38569471, PMCID: PMC11025492, DOI: 10.1016/j.cmet.2024.03.002.Peer-Reviewed Original ResearchConceptsUnhealthy obesityPlasma PAI-1 concentrationAbnormalities associated with obesityMetabolically healthy obesityMetabolically unhealthy obesityPAI-1 concentrationsMetabolic heterogeneity of obesityHeterogeneity of obesityMetabolically healthy leanSystemic metabolic functionCharacteristics of peopleDecreased oxidative stressHealthy obesityCardiometabolic characteristicsAdipose tissue biologyHealthy leanSkeletal muscle biologyPlasma adiponectinPlasma glucoseObesityMetabolic heterogeneityOxidative stressPotential mechanismsTissue biologyMuscle biology
2022
Bioactive lipids and metabolic syndrome—a symposium report
DeVito LM, Dennis EA, Kahn BB, Shulman GI, Witztum JL, Sadhu S, Nickels J, Spite M, Smyth S, Spiegel S. Bioactive lipids and metabolic syndrome—a symposium report. Annals Of The New York Academy Of Sciences 2022, 1511: 87-106. PMID: 35218041, PMCID: PMC9219555, DOI: 10.1111/nyas.14752.Peer-Reviewed Original ResearchConceptsBioactive lipidsMetabolic syndromeCardiometabolic conditionsCardiovascular diseaseAnimal modelsDietary lipidsLipid metabolismMetabolic homeostasisMultitude of functionsLipidomic approachLipid pathwaysContinued investigationSyndromeMolecular functionsSymposium reportGenetic studiesLipidsPathwayInflammationGreater understandingDiseaseLiverMacrophagesLipogenesis
2021
Therapeutic potential of mitochondrial uncouplers for the treatment of metabolic associated fatty liver disease and NASH
Goedeke L, Shulman GI. Therapeutic potential of mitochondrial uncouplers for the treatment of metabolic associated fatty liver disease and NASH. Molecular Metabolism 2021, 46: 101178. PMID: 33545391, PMCID: PMC8085597, DOI: 10.1016/j.molmet.2021.101178.Peer-Reviewed Original ResearchConceptsFatty liver diseaseLiver diseaseSmall molecule mitochondrial uncouplersTherapeutic potentialMitochondrial uncouplerNon-human primate studiesType 2 diabetesWide therapeutic indexSystemic toxicity concernsTreatment of MetabolicCell-specific effectsInsulin resistanceTherapeutic indexMetabolic diseasesNonalcoholic hepatosteatosisSustained increaseToxicity concernsPrimate studiesDiseaseTherapeutic developmentMitochondrial inefficiencyNutrient oxidationATP productionTreatmentTissue
2007
The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome
Petersen KF, Dufour S, Savage DB, Bilz S, Solomon G, Yonemitsu S, Cline GW, Befroy D, Zemany L, Kahn BB, Papademetris X, Rothman DL, Shulman GI. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proceedings Of The National Academy Of Sciences Of The United States Of America 2007, 104: 12587-12594. PMID: 17640906, PMCID: PMC1924794, DOI: 10.1073/pnas.0705408104.Peer-Reviewed Original ResearchMeSH KeywordsCytokinesFastingGlycogenHormonesHumansInsulin ResistanceMagnetic Resonance ImagingMetabolic SyndromeMuscle, SkeletalConceptsPlasma high-density lipoprotein concentrationsHigh-density lipoprotein concentrationsHepatic de novo lipogenesisMuscle glycogen synthesisInsulin resistanceInsulin-resistant subjectsPlasma triglyceride concentrationsDe novo lipogenesisMetabolic syndromeAtherogenic dyslipidemiaIL-6Lipoprotein concentrationsTNF-alphaPlasma concentrationsTriglyceride concentrationsNovo lipogenesisGlycogen synthesisIntraabdominal fat volumeSkeletal muscle insulin resistanceSkeletal muscleProtein 4Skeletal muscle glycogen synthesisMuscle insulin resistanceHepatic triglyceride synthesisIntraabdominal obesity